

**CIRM Scientific and Medical Research Funding Working Group
Biographical information of candidates nominated to serve as
Scientific Members of the Working Group**

Daniel H. Kim, MD

Dr. Kim is a fellowship-trained, board-certified neurosurgeon who is an expert in minimally invasive spinal surgery, both endoscopic and robotic; peripheral nerve surgery; and complex spinal reconstruction. He is currently Director of Reconstructive Spinal and Peripheral Nerve Surgery at the Mischer Neuroscience Institute and Professor in the Vivian L. Smith Department of Neurosurgery at the University of Texas Health Science Center at Houston (UTHealth) Medical School. Dr. Kim has won numerous awards and honors, authored hundreds of papers and published seventeen surgical textbooks. He is a preeminent researcher in peripheral nerve repair through nerve transfer and nerve graft, and is also recognized for his work in neurorehabilitation through robotics and cortical stimulation, spinal biomechanics and innovative neuromodulation treatments for chronic pain. Dr. Kim is also an adjunct professor in the Department of Bioengineering, Electrical Engineering and Computer Science at Rice University.

Before his appointment at the Mischer Neuroscience Institute, Dr. Kim served as a Professor in the Departments of both Neurosurgery and Orthopedic Surgery at the Baylor College of Medicine (BCM). He was the Director of Spinal Neurosurgery and Reconstructive Peripheral Nerve Surgery for both programs. Before that, he was a full Professor at the Stanford University School of Medicine.

A graduate of the University of Oklahoma in chemical engineering, Dr. Kim received his medical degree at Tulane University School of Medicine before completing his neurosurgery residency at Louisiana State University. He completed a fellowship in spinal surgery at the University of Florida with Richard Fessler, MD, PhD.

Andra E. Miller, PhD

Dr. Miller is Director of Cellular and Gene Therapies at the Biologics Consulting Group. In this capacity, she provides consultation on regulatory strategies to facilitate rapid development of cell and gene based therapies and assessment of current Good Manufacturing Practices (cGMP) compliance. Prior to this she spent 9 years at the Center for Biologics Evaluation and Research (CBER) in the Food and Drug Administration (FDA) as Expert Microbiologist and Gene Therapy Group Leader in the Division of Cellular and Gene Therapies, where she performed product review and was involved in policy development in the fields of cell and gene therapy. Dr. Miller received her BA degree in Biology from Manhattanville College and her PhD in Genetics from the George Washington University.

While at the FDA, Dr. Miller received a number of awards including the CBER Scientific Achievement Award, the Center Director's Distinguished Service Award, the FDA Commendable Service Award, the FDA Award, and the Commissioner's Special Citation. She is active in professional societies as a current member of the

International Society for Cellular Therapy and The American Society for Gene Therapy (ASGT). She has also served on the USP Gene and Cell Therapies Advisory Panel, the NIH Recombinant DNA Advisory Committee (RAC), and a number of planning and advisory committees for ASGT and other organizations.

Nancy L. Parenteau, PhD

Dr. Parenteau is currently the Co-founder, President, CSO, and Chairman of Ingenium BioTherapy Corporation. Ingenium BioTherapy (IBT) is a next generation oncology company designing high-curative-potential Cytotoxic T lymphocyte (CTL)-based immunotherapies for advanced epithelial cancers. She is also the Co-founder and Managing Member of Parenteau BioConsultants, LLC. Parenteau BioConsultants provides in biotechnology strategy, advice and assistance with a technical specialty in biological product development. The firm offers information and analysis for strategic decision-making, management and technical consulting, and professional coaching and training.

Dr. Parenteau received her BA degree in Zoology from the University of Vermont, her MS degree from Rivier College, and her PhD in Anatomical Sciences with specialization in Developmental Biology from Georgetown University. She was a Post-Doctoral Associate in the Laboratory of Toxicology at Harvard School of Public Health before joining Organogenesis as Group Leader, Cell Biology where she moved up through the ranks to Senior Vice President and Chief Scientific Officer. Following her tenure at Organogenesis, Dr. Parenteau joined Amaranth Bio, Inc. as CEO, President and Co-founder before moving to her current companies.

Dr. Parenteau's current research interest is in the functional identification of cancer stem and progenitor cells, i.e., the regeneration-capable cells of a tumor. This research is based on 30 years of industry-based work on the regeneration and differentiation of normal human epithelial cell populations, in particular, the activation, expansion and subsequent differentiation of a regenerative progenitor pool. This insight is now being applied to tumor biology with the goal of being able to functionally identify the regeneration-capable cells of a cancer with high fidelity. Her goal is to use these populations as tools to discern clinically relevant targets for curative adoptive immunotherapy.

Dr. Parenteau's clinical and career interests are in using the knowledge gained from this research to advance the commercial development of high-curative-potential CTL-based cancer immunotherapies for advanced epithelial cancers. She also serves as a consultant and scientific advisor to regenerative medicine companies.